HYPAQUE
LOE ApproachingNDAORAL, RECTALSOLUTION
Approved
Mar 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1956.
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE is a water-soluble iodinated contrast medium (diatrizoate meglumine) used for retrograde cystourethrography and voiding cystourethrography to visualize the urinary bladder and detect cystoureteric reflux. Administered orally or rectally as a solution, it provides radiopacity of urinary tract contents without systemic absorption under normal conditions. The drug works by simple diffusion into target tissues and is excreted unchanged primarily through renal glomerular filtration.
LOE Approaching
Product approaching loss of exclusivity with minimal linked commercial roles; team size and resource allocation likely declining.
Mechanism of Action
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.